As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
ApexOnco Front Page
Recent articles
Summit and Nuvalent have scored prized plenary spots.
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
PD-(L)1 x VEGF bispecifics prove a big draw.
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
